ACLARION, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ACLARION, INC. (ACON) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $4.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- ACLARION, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $6.99M, a 51.11% decline year-over-year.
- ACLARION, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $14.30M, a 1186.17% increase year-over-year.
- ACLARION, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $1.11M.
- ACLARION, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$1.02M.
- ACLARION, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $11.58M.
- ACLARION, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$567.41K.
- ACLARION, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$451.74K, a 143.85% decline from fiscal 2022.
- ACLARION, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $1.03M, a 135.47% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.27M 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $6.99M 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $11.58M 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | $10.90M 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $12.39M 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | $14.30M 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | -$567.41K 10-K · filed 2026-03-18 | ||||
| 2024-09-30 | $291.03K 10-Q · filed 2025-11-12 | $291.03K 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $151.62K 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | $1.11M 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -$451.74K 10-K · filed 2025-04-09 | ||||
| 2023-09-30 | -$1.31M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | -$868.29K 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | -$1.02M 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $1.03M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $2.21M 10-Q · filed 2023-11-14 | $2.21M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $3.35M 10-Q · filed 2023-08-25 | ||||
| 2022-03-31 | -$392.08K 10-Q · filed 2023-07-03 | ||||
| 2021-12-31 | $437.55K 10-K/A · filed 2023-06-12 | ||||
| 2021-09-30 | $1.29M 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $2.08M 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $48.91K 10-Q · filed 2022-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |